Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (672)

« Back to Publications

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

Goodwin GM. et al, (2026), J Affect Disord, 393

Dose-dependent pharmacological mechanisms within the Neuroscience-based Nomenclature: a new concept to facilitate neuroscience-based prescribing.

Zemach S. et al, (2026), Lancet Psychiatry

ntidepressant drugs have pharmacological- and time-dependent effects on reinforcement learning in healthy volunteers: An 8 weeks randomized double-blind placebo-controlled study.

Berkovitch L. et al, (2026), medRxiv

Borderline personality disorder, but not euthymic bipolar disorder, is associated with a failure to sustain reciprocal cooperative behaviour: implications for spectrum models of mood disorders (vol 45, pg 1591, 2025)

Saunders KEA. et al, (2026), PSYCHOLOGICAL MEDICINE, 55

brief, digital, imagery-competing task intervention for stopping intrusive memories in trauma-exposed health-care staff during the COVID-19 pandemic in the UK: a Bayesian adaptive randomised clinical trial

Beckenstrom A. et al, (2025), The Lancet Psychiatry

The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience: A Retrospective Analysis.

Kirlić N. et al, (2025), J Clin Psychopharmacol

Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.

Modlin NL. et al, (2025), EClinicalMedicine, 90

Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial.

McGowan NM. et al, (2025), J Psychopharmacol

Non-mental health inpatient and emergency care hospital costs associated with four mental disorders in Europe: a modelling study.

Wienand D. et al, (2025), Lancet Psychiatry, 12, 513 - 523

Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing.

Dougherty RF. et al, (2025), Psychopharmacology (Berl), 242, 1553 - 1561

Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder.

Goodwin GM. et al, (2025), J Clin Psychiatry, 86

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Goodwin GM. et al, (2025), J Affect Disord, 372, 523 - 532

single dose of lamotrigine induces a positive memory bias in healthy volunteers

Zghoul T. et al, (2025), Psychological Medicine, 55

Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions.

Kirlić N. et al, (2025), Am J Psychiatry, 182, 126 - 132

Non-mental health hospital costs associated with selected serious mental health conditions in Europe

Wienand D. et al, (2025), EUROPEAN JOURNAL OF PUBLIC HEALTH, 35

Load More

1
2
3
4
5
6
7
...
»